Download full-text PDF

Source
http://dx.doi.org/10.1097/INF.0000000000004191DOI Listing

Publication Analysis

Top Keywords

sars-cov-2 serology
4
serology severity
4
severity mis-c
4
mis-c case
4
case series
4
sars-cov-2
1
severity
1
mis-c
1
case
1
series
1

Similar Publications

Currently commercial colorimetric paper lateral flow immunoassays exhibit insufficient limit of detection (LOD) and limited clinical sensitivity toward the detection of SARS-CoV-2 antigens, which causes a high false negative rate. To mitigate this issue, a new plasmon-enhanced fluorescence probe was developed for paper lateral flow strips (PLFSs). The probe is made of a sandwich-structured Ag-core@silica@dye@silica-shell nanoparticle in which fluorescent dyes are sandwiched between the plasmonic Ag core and the silica outer shell, and the separation distance between the Ag core and the dye molecules is controlled by the silica space layer.

View Article and Find Full Text PDF

The recently detected Omicron BA.2.86 lineage contains more than 30 amino acid mutations relative to BA.

View Article and Find Full Text PDF

Establishing quality assurance for COVID-19 antigen tests in the Indo Pacific Region: A multi-site implementation study.

Diagn Microbiol Infect Dis

December 2024

Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.

Background: Quality assurance programs (QAPs) are used to evaluate the analytical quality of a diagnostic test and provide feedback to improve quality processes in testing. Rapid diagnostic tests were used in both laboratory and non-laboratory settings to diagnose COVID-19, although varied in reported performance. We aimed to design and implement a QAP for antigen rapid diagnostic tests (Ag-RDTs) for COVID-19 in Cambodia, Lao PDR, and Papua New Guinea.

View Article and Find Full Text PDF

Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial.

J Infect

January 2025

Radcliffe Department of Medicine and BRC Haematology Theme, University of Oxford, Oxford, UK; Microbiology Services, NHS Blood and Transplant, Colindale, UK; Infection and Immunity, University College of London, London, UK.

Objectives: Convalescent plasma (CP) treatment of COVID-19 has shown significant therapeutic effect only when administered early. We investigated the importance of patient and CP seroprofiles on treatment outcome in REMAP-CAP CP trial.

Methods: We evaluated neutralising antibodies (nAb), anti-spike (S) IgM, IgG, IgG avidity, IgG fucosylation and respiratory viral loads in a sub-set of patients (n=80) and controls (n=51) before and after transfusion, comparing them to those in the CP units (n=157) they received.

View Article and Find Full Text PDF

The ongoing emergence of SARS-CoV-2 variants, combined with antigen exposures from different waves and vaccinations, poses challenges in updating COVID-19 vaccine antigens. We collected 206 sera from individuals with vaccination-only, hybrid immunity, and single or repeated omicron post-vaccination infections (PVIs), including non-JN.1 and JN.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!